Prostate-specific membrane antigen cars and methods of use thereof

US10780120B2 · kind B2 · utility

Assignee

• The Trustees of the University of Pennsylvania · US

Inventors

• Yangbing Zhao · Cherry Hill, US
• Szu Hua Sharon Lin · Philadelphia, US
• Xiaojun Liu · Nanhu, CN
• Anne Chew · Cherry Hill, US

Key dates

• Filing date: Mar 5, 2019
• Grant date: Sep 22, 2020
• Expiry date: Mar 5, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.